by myTomorrows | 27 Jun 2019
myTomorrows and Immodulon to develop Expanded Access Programme
Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 - myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration to develop an Expanded Access Programme (EAP) for the unlicensed investigational drug IMM-101.
Immodulon is progressing IMM-101 in a clinical development programme as a potential treatment in several cancer settings. The Expanded Access Programme will support the supply in Europe of IMM-101, an unlicensed medicine, when prescribed on a Named Patient basis for patients who have no other treatment options.
Steve Glass, COO of myTomorrows said, “I am delighted that myTomorrows is to strengthen the relationship with Immodulon. With our unique online platform, combined with our global capabilities of supporting expanded access and real-world data collection we aim to accelerate access to a medicine in development.”
Dr Jaap Kampinga, CEO of Immodulon commented, “We are progressing a clinical development programme investigating IMM-101 as a potential treatment in several cancer settings. With this programme ongoing, we also wish to put in place the appropriate infrastructure to ensure that cancer patients, who have no other treatment options, can access this medicine as efficiently as possible. As an expert in providing unlicensed medicines to patients through Expanded Access Programmes, myTomorrows is well placed to help us achieve this.”
Notes to Editor
About Expanded Access Programmes
An Expanded Access Programme (EAP), also known as Managed Access Programme, supports in a compliant and controlled way the treatment with a medicine currently not licensed in a patient’s country of residence. Such treatment can be an option for patients who are in high unmet medical need and have exhausted all registered treatment options and cannot participate in a clinical trial.
myTomorrows operates as a two-sided platform. It serves the interests of both patients and HCPs, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialised in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 20 Early Access Programmes over the past 5 years, in more than 30 countries across 5 continents. For more information, please visit www.mytomorrows.com.
For enquiries about myTomorrows or Expanded Access, please contact our medical team via email@example.com.
Immodulon Therapeutics Ltd. is a privately-owned clinical-stage immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system by several mechanisms, including via Toll-like receptors. Its mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and other standard-of-care treatments, it is expected to enhance their efficacy without increasing the safety burden for the patient. For more information about Immodulon, please visit www.immodulon.com.
For Immodulon, please contact:
Dr Jaap Kampinga, CEO
T: +44 (0) 20 3137 6346
Simon Conway / George Kendrick
+44 (0) 20 3727 1000
For myTomorrows, please contact:
Michel van Harten MD, CMO
T: +31 (0) 88 5253 888